Orbicular’s Ozempic generic gets U.S. FDA tentative nod

A generic version of Ozempic (semaglutide injection) developed by Hyderabad-based Orbicular Pharmaceutical Technologies in partnership with Florida-headquartered Apotex Corp. has received tentative approval from the U.S. Food and Drug Administration (FDA).

The product will be marketed and commercialised in the U.S. by Apotex, which is the ANDA applicant, complex peptide-based generics developer Orbicular said in a release.